Timing of Endoscopy in Cirrhotic Patients with Acute Variceal Bleeding

NCT ID: NCT06031402

Last Updated: 2025-02-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

368 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-04

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endoscopy is important for the diagnosis and treatment of acute upper gastrointestinal bleeding (AUGIB), especially acute variceal bleeding (AVB), in patients with liver cirrhosis. However, the optimal timing of endoscopy remains controversial, primarily because the currently available evidence is of poor quality, and the definition of early endoscopy is also very heterogeneous among studies. Herein, a multicenter randomized controlled trial (RCT) is performed to explore the impact of timing of endoscopy on the outcomes of cirrhotic patients with AVB.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 368 cirrhotic patients presenting with AUGIB that is highly suspected to be from AVB will be enrolled. They will be stratified according to the severity of liver function and hemodynamic status at admission, and randomly assigned at a 1:1 ratio into early (within 12 hours after admission) and delayed (within 12-24 hours after admission) endoscopy groups within each stratum. The primary outcomes include the rates of 5-day failure to control bleeding after admission and 6-week rebleeding. The secondary outcomes include 6-week mortality and incidence of adverse events.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Upper Gastrointestinal Bleeding Acute Variceal Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Before enrollment, all patients and/or their relatives will be informed about the study protocol, and sign the written informed consent forms. Eligible patients are randomly assigned at a ratio of 1:1 to early endoscopy group (within 12 hours after admission) and delayed endoscopy group (within 12-24 hours after admission)
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early endoscopy group

Intervention of endoscopy is within 12 hours after admission

Group Type EXPERIMENTAL

Endoscopy

Intervention Type PROCEDURE

Endoscopy

Delayed endoscopy group

Intervention of endoscopy is within 12-24 hours after admission

Group Type ACTIVE_COMPARATOR

Endoscopy

Intervention Type PROCEDURE

Endoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopy

Endoscopy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients with AUGIB which is highly suspected to be caused by gastroesophageal variceal rupture;
2. patients with a diagnosis of liver cirrhosis based on imaging and pathology;
3. patients and/or their relatives who sign informed consents;
4. patients' age ≥18 years.

Exclusion Criteria

1. patients who have undergone endoscopy at other hospitals before admissions;
2. patients' hemodynamics are unstable after resuscitation;
3. patients with severe cardiovascular or cerebrovascular diseases or renal injury;
4. patients who have taken anticoagulants or antiplatelet drugs within 2 weeks before admissions, or are diagnosed with severe hematological diseases;
5. patients with human immunodeficiency virus or other acquired or congenital immune deficiency diseases;
6. patients with mental illness;
7. pregnancy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

General Hospital of Shenyang Military Region

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xingshun Qi

Director of Department of Gastroenterology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xingshun Qi, MD

Role: PRINCIPAL_INVESTIGATOR

General Hospital of Shenyang Military Area

Yiling Li, MD

Role: PRINCIPAL_INVESTIGATOR

First Hospital of China Medical University

Bimin Li, MD

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Nanchang University

Xuefeng Luo, MD

Role: PRINCIPAL_INVESTIGATOR

West China Hospital

Xiaofeng Liu, MD

Role: PRINCIPAL_INVESTIGATOR

The 960th Hospital of the Chinese People's Liberation Army

Chunqing Zhang, MD

Role: PRINCIPAL_INVESTIGATOR

Affiliated Provincial Hospital of Shandong First Medical University

Mingkai Chen, MD

Role: PRINCIPAL_INVESTIGATOR

People's Hospital of Wuhan University

Derun Kong, MD

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Anhui Medical University

Fernando G Romeiro, MD

Role: PRINCIPAL_INVESTIGATOR

Botucatu Medical School

Andrea Mancuso, MD

Role: PRINCIPAL_INVESTIGATOR

Azienda di Rilievo Nazionale ad Alta Specializzazione Civico-Di Cristina-Benfratelli

Nahum Méndez-Sánchez, MD

Role: PRINCIPAL_INVESTIGATOR

Medica Sur Clinic and Foundation

Enqiang Linghu, MD

Role: PRINCIPAL_INVESTIGATOR

The First Medical Center of Chinese PLA General Hospital

Yunhai Wu, MD

Role: PRINCIPAL_INVESTIGATOR

The Sixth People's Hospital of Shenyang

Metin Basaranoglu, MD

Role: PRINCIPAL_INVESTIGATOR

Bezmialem Vakif University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)

Shenyang, Liaoning, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xingshun Qi, MD

Role: CONTACT

18909881019

Xingshun Qi, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xingshun Qi, MD

Role: primary

18909881019

Qianqian Li

Role: backup

13940307473

References

Explore related publications, articles, or registry entries linked to this study.

Bai Z, Wang R, Cheng G, Ma D, Ibrahim M, Chawla S, Qi X. Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: a systematic review with meta-analysis. Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e868-e876. doi: 10.1097/MEG.0000000000002282.

Reference Type BACKGROUND
PMID: 35048654 (View on PubMed)

Peng Y, Qi X, Dai J, Li H, Guo X. Child-Pugh versus MELD score for predicting the in-hospital mortality of acute upper gastrointestinal bleeding in liver cirrhosis. Int J Clin Exp Med. 2015 Jan 15;8(1):751-7. eCollection 2015.

Reference Type BACKGROUND
PMID: 25785053 (View on PubMed)

Peng Y, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016 Feb;95(8):e2877. doi: 10.1097/MD.0000000000002877.

Reference Type BACKGROUND
PMID: 26937922 (View on PubMed)

Li Y, Li H, Zhu Q, Tsochatzis E, Wang R, Guo X, Qi X. Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1334-1341. doi: 10.1097/MEG.0000000000001524.

Reference Type BACKGROUND
PMID: 31524777 (View on PubMed)

Qi X, Li Y, Li B, Luo X, Liu X, Zhang C, Chen M, Kong D, Wu Y, Romeiro FG, Basaranoglu M, Zhang J, Li Q, Wang R, Shao X, Guan L, Wang N, You Y, He M, Wang X, Huang J, Wu W, Li Q, Zhang M, Wang G, Zhang C, Cheng D, Zhang Q, Mei X, Sun N, Ban Y, Marcondes MB, Yamashiro FDS, Mutlu E, Zheng Z, Peng M, Xu W, Li Z, Chai L, Linghu E. Timing of endoscopy in cirrhotic patients with acute variceal bleeding: protocol of a multicenter randomized controlled trial. Therap Adv Gastroenterol. 2024 Nov 13;17:17562848241295452. doi: 10.1177/17562848241295452. eCollection 2024.

Reference Type DERIVED
PMID: 39539489 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XHNKKY-ENDO-AVB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.